Ainos, Inc. announced the signing of a Memorandum of Understanding (MOU) with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation. This strategic partnership aims to advance the manufacturing and Taiwan market promotion of Ainos' Sjögren's syndrome drug, VELDONA. Taiwan Tanabe Seiyaku brings extensive pharmaceutical development and manufacturing expertise to the collaboration.
The global Sjögren's syndrome market is projected to reach billions of dollars in the next five years, indicating a significant unmet need for effective treatments. VELDONA, a low-dose oral interferon-alpha, has shown potential in clinical trials by alleviating symptoms and improving quality of life. This partnership is expected to accelerate the market introduction of VELDONA in Taiwan and sets the stage for future global expansion.
The collaboration will define specific details and responsibilities through a formal contract, paving the way for long-term success. Ainos anticipates that this partnership will enhance its market valuation and growth potential, potentially opening opportunities in other autoimmune diseases. This strategic alliance is a key step in commercializing VELDONA and addressing a pressing market demand.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.